Bayer AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bayer AG with three other
pharmaceutical manufacturers in Europe:
sales of 49.16 billion Swiss Francs [US$50.89 billion]
of which 66%
was Innovative Medicines),
(36.20 billion Euro [US$44.81 billion]
of which 83%
was Pharmaceuticals), and
based in the United Kingdom
(£30.19 billion [US$43.12 billion]
of which 57%
Bayer AG reported sales of 35.02 billion Euro (US$43.34 billion)
December of 2017.
decrease of 25.1%
versus 2016, when the company's sales were 46.77 billion Euro.
Contributing to the drop in overall sales was the 3.4% decline
in Cropscience, from 9.92 billion Euro to 9.58 billion Euro.
There were also decreases in sales in
Consumer Care (down 2.9% to 5.86 billion Euro)
However, these declines were partially offset by the increase in sales of
Pharmaceuticals and Biological Products (up 2.6% to 16.85 billion Euro)
Animal Health (up 3.2% to 1.57 billion Euro)
All Other Segments (up 9.6% to 1.14 billion Euro)
Reconciliations (up 166.7% to 16.00 million Euro)